外周血T淋巴细胞亚群与接受卡瑞利珠单抗治疗的晚期非小细胞肺癌患者预后的关系  

Relationship Between Peripheral Blood T Lymphocyte Subsets and Prognosis of Patients with Advanced Non-small Cell Lung Cancer Treated with Camrelizumab

作　　者：董长鸿 封岩 江艳婷 高洁[3] 蒋晓东 DONG Changhong;FENG Yan;JIANG Yanting;GAO Jie;JIANG Xiaodong(Department of Oncology,the Afiliated Lianyungang Hospital of Xuzhou Medical University,Lianyungang 222006,China;Department of Respiratory and Critical Care Medicine,Lianyungang Clinical College of Nanjing Medical University,Lianyungang 222006,China;Department of Oncology,Lianyungang Clinical College of Nanjing Medical University,Lianyungang 222006,China)

机构地区：[1]徐州医科大学附属连云港医院,连云港市第一人民医院肿瘤科,连云港222006 [2]南京医科大学连云港临床医学院,连云港市第一人民医院呼吸与危重症医学科,连云港222006 [3]南京医科大学连云港临床医学院,连云港市第一人民医院肿瘤科,连云港222006

出　　处：《肿瘤防治研究》2024年第3期185-190,共6页Cancer Research on Prevention and Treatment

基　　金：江苏省研究生科研与实践创新计划(SJCX23_1415);江苏省重点研发计划(BE2017648)。

摘　　要：目的探索外周血T淋巴细胞亚群与接受卡瑞利珠单抗治疗的晚期非小细胞肺癌(NSCLC)患者预后的关系。方法回顾性收集接受卡瑞利珠单抗治疗的88例晚期NSCLC患者资料。分别收集患者治疗前和治疗后2个月的外周血淋巴细胞亚群相对计数,使用Kaplan-Meier曲线和Cox回归分析研究外周血T淋巴细胞亚群与PFS和OS之间的关系。结果有反应组患者治疗前外周血CD4+/CD8+比值高于无反应组(P=0.038),而CD8+T淋巴细胞百分比低于无反应组(P=0.036);生存分析显示治疗前CD4+/CD8+比值越高,患者PFS和OS越长(P=0.001,P=0.023)。多变量Cox分析显示,治疗前CD4+/CD8+比值是预测PFS和OS的因素。此外,治疗后CD4+/CD8+比值、CD4+T淋巴细胞百分比越高,患者PFS越长(P=0.005,0.015);CD8+T淋巴细胞百分比越低,患者PFS和OS越长(P=0.001,P=0.016)。结论外周血CD4+/CD8+比值能够预测接受卡瑞利珠单抗治疗的NSCLC患者的生存情况。Objective To explore the relationship between peripheral blood T lymphocyte subsets and prognosis of patients with advanced non-small cell lung cancer(NSCLC)who received treatment with camrelizumab.Methods We retrospectively collected data from 88 patients with advanced NSCLC who underwent camrelizumab treatment.Peripheral blood lymphocyte subsets were collected from patients before and two months after treatment.Kaplan-Meier curves and Cox regression analysis were employed to inves-tigate the relationship between peripheral blood T lymphocyte subsets and PFS and OS.Results Compared with non-responder group,the baseline peripheral blood CD4+/CD8+ratio was higher(P-0.038),while the CD8+T lymphocyte percentage was lower(P-0.036)in the responder group.Kaplan-Meier curves showed that a high baseline CD4+/CD8+ratio was associated with long PFS and OS(P=0.001,P=0.023).Multivar-iate Cox analysis revealed that the baseline CD4+/CD8+ratio was a significant predictor for PFS and OS.Additionally,a high post-treatment CD4+/CD8+ratio and high CD4+T lymphocyte percentage were associated with long PFS(P-0.005,P-0.015),whereas a low post-treatment CD8+T lymphocyte percentage was associated with long PFS and OS(P=0.001,P=0.016).Conclusion The peripheral blood CD4+/CD8+ratio can serve as a predictive factor for survival of patients with NSCLC treated with camrelizumab.

关 键 词：非小细胞肺癌 CD4+/CD8+比值 CD4+T淋巴细胞 CD8+T淋巴细胞 抗PD-1治疗 卡瑞利珠单抗 

分 类 号：R734.2[医药卫生—肿瘤]